Determination of Regulatory Review Period for Purposes of Patent Extension; FYARRO

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for FYARRO, a human drug product, and is publishing this notice as required by law. The FDA made this determination due to the submission of an application to the U.S. Patent and Trademark Office (USPTO) for patent extension.